drugset / Trial / NCT04475588
Efficacy and Safety of Itolizumab in COVID-19 Complications
RandomizedParallel-groupOpen-labelTreatment
Summary
Randomized, Parallel Group, Active Controlled Trial
Timeline
- Start
- 2020-05-01
- Primary completion
- 2020-07-07
- Completion
- 2020-07-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Itolizumab | Monoclonal antibody | 0.8 mg/kg | Intravenous |
| Subject | Itolizumab | Monoclonal antibody | 1.6 mg/kg | Intravenous |
| Background | Hydroxychloroquine | Small molecule | — | — |